
CLSA has upgraded its rating on Dr. Lal Pathlabs to ‘Outperform’ and raised its target price to ₹3,240, indicating a 14% potential upside from the current market price (CMP) of ₹2,847.85.
Key highlights:
- Continuous improvement in volume growth, which bottomed out in FY24, coupled with steady pricing trends.
- The stock is currently down 22% from its previous high, which CLSA believes is overdone.
- Dr. Lal Pathlabs now trades at a discount to its peers, compared to the premium it commanded earlier.
At its CMP of ₹2,847.85, the stock is trading approximately 12% below CLSA’s revised target of ₹3,240.
Disclaimer: This article is for informational purposes only and does not constitute financial advice.